To explore the role of specific biomarkers and biological determinants, including tissue-based and circulating biomarkers, in guiding clinical decision-making for genitourinary cancer treatments.
Key Findings:
Current biomarkers are heterogeneous and insufficient for capturing treatment response complexity, limiting personalized treatment.
Tumor biology and microenvironment significantly influence therapeutic outcomes, necessitating a deeper understanding for effective interventions.
Metabolic pathways actively drive immune modulation and treatment response, indicating a need for integrated therapeutic approaches.
Interpretation:
The transition from treatment-centered to biology-driven models in genitourinary oncology is essential for improving patient outcomes, highlighting the inadequacy of current biomarkers in capturing the dynamic nature of tumor evolution.
Limitations:
Existing biomarkers are often static and fragmented, which hampers their utility in real-time clinical decision-making.
Current studies primarily focus on bladder cancer, limiting broader applicability and understanding of other genitourinary malignancies.
Conclusion:
Future advancements in genitourinary oncology require integrative predictive models that combine multi-omics data and dynamic tumor characterization to enhance personalized treatment approaches, addressing the urgent need for improved patient outcomes.
